Dr. Joshua Mansour is a board-certified hematologist/oncologist working and in the field of hematopoietic stem cell transplantation and cellular immunotherapy in Stanford, California. Recently he has managed to have over 10 recent abstracts and over 10 recent manuscripts published in esteemed journals and given countless presentations at conferences and other institutions. He has helped design and implement clinical studies to evaluate current treatment plans, collaborated on grant proposals, and lead multi-institutional retrospective studies that have been published.
Will Artificial Intelligence Soon Replace Doctors?
With approximately 160,000 deaths in 2018 due to lung cancer, it is the most common cause of cancer death in the United States. The U.S Preventive Services Task Force has set out new guidelines for the use of low dose computed tomography (LDCP) that have recently been updated for individuals at high risk of having lung cancer. Lung cancer screening using this computed tomography testing has been shown to reduce death by 20-40%. However, one ongoing issue with the use of this screening exam has been the rate of false positives (a result that indicates that a person does have a disease when the actually do not). Although LDCP has helped immensely in early detection, it has been found that about one-quarter of the suspected nodules are actually not cancerous.
- Monday, June 3, 2019